Drug intelligence / Profile preview

9MW1911

Development stage: Phase 2
Lead developer: Mabwell
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

9MW1911 is a recombinant humanized anti-ST2 monoclonal antibody developed by Mabwell Bioscience. It targets the ST2 receptor, which is involved in the signaling pathway mediated by interleukin-33 (IL-33), thereby inhibiting inflammatory reactions. It is primarily being investigated for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Targets

IL1RL1 (Interleukin 1 receptor-like 1 protein)

Beyond the preview

Go deeper on 9MW1911.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9MW1911.

Explore the full profile